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What is already known on this topic?
 ► Children exposed to certain antiepileptic drugs 
(AEDs) in utero can have physical and cognitive 
sequelae.
 ► Not all children exposed experience problems 
and there is a likely genetic predisposition.
 ► Fetal anticonvulsant syndrome (FACS) is a 
diagnosis of exclusion and current guidance is 
to perform chromosomal analysis as a baseline; 
however, genetic technologies have significantly 
advanced since these guidelines.
What this study adds?
 ► FACS remains a diagnosis of exclusion, and 
higher resolution analysis of patients’ genomes 
may be warranted to better understand FACS 
susceptibility and exclude other primary genetic 
causes.
 ► Whole exome sequencing, while not being able 
to exclude a genetic disorder completely in an 
individual has facilitated the identification of 
pathogenic variants in several children exposed 
to AEDs in utero, which may contribute to their 
phenotype.
 ► The chance of identifying an underlying genetic 
condition is likely to be higher when children 
have features which are more severe than or 
atypical for FACS. Some of the genetic variants 
identified in patients diagnosed with FACS 
have counselling and clinical management 
implications, highlighting the importance of 
their identification.
AbsTrACT
Introduction Fetal anticonvulsant syndrome (FACS) 
describes the pattern of physical and developmental 
problems seen in those children exposed to certain 
antiepileptic drugs (AEDs) in utero. The diagnosis of FACS 
is a clinical one and so excluding alternative diagnoses 
such as genetic disorders is essential.
Methods We reviewed the pathogenicity of reported 
variants identified on exome sequencing in the 
Deciphering Developmental Disorders (DDD) Study in 42 
children exposed to AEDs in utero, but where a diagnosis 
other than FACS was suspected. In addition, we analysed 
chromosome microarray data from 10 patients with FACS 
seen in a Regional Genetics Service.
results Seven children (17%) from the DDD Study 
had a copy number variant or pathogenic variant in a 
developmental disorder gene which was considered to 
explain or partially explain their phenotype. Across the 
AED exposure types, variants were found in 2/15 (13%) 
valproate exposed cases and 3/14 (21%) carbamazepine 
exposed cases. No pathogenic copy number variants 
were identified in our local sample (n=10).
Conclusions This study is the first of its kind to 
analyse the exomes of children with developmental 
disorders who were exposed to AEDs in utero. Though 
we acknowledge that the results are subject to bias, 
a significant number of children were identified with 
alternate diagnoses which had an impact on counselling 
and management. We suggest that consideration is 
given to performing whole exome sequencing as part of 
the diagnostic work-up for children exposed to AEDs in 
utero.
bACkgrOund
The term fetal anticonvulsant syndrome (FACS) has 
been coined to describe children who have been 
exposed to antiepileptic drugs (AEDs) in utero and 
have a characteristic pattern of physical and cogni-
tive difficulties.1 Prior to women with epilepsy 
becoming pregnant, it is essential to optimise 
AED therapy to achieve a low risk of fetal harm 
by avoiding AED polytherapy, achieving seizure 
control at the lowest possible dose and avoiding 
drugs which are highly teratogenic.
Certain AEDs have been demonstrated to be 
associated with elevated rates of major congen-
ital malformations. Current evidence suggests 
significantly increased risks of major congenital 
malformations for valproate (VPA), carbamazepine 
(CBZ), phenytoin (PHT), and topiramate. Adverse 
outcomes associated with human teratogens are 
typically wider than major structural malforma-
tions and often include functional deficits such as 
reduced intellectual functioning, altered growth 
parameters and more subtle physical malforma-
tions, occurring in a recognisable and consistent 
pattern.2 To date, three anticonvulsant syndromes 
have been reported in the literature: fetal hydan-
toin syndrome,3 fetal valproate syndrome4 and fetal 
carbamazepine syndrome.5 All three have distinct 
presentations and include major organ malforma-
tions, more minor or functional physical difficulties 
and neurodevelopmental deficits.
The diagnosis of FACS, which is a diagnosis 
of exclusion, depends on the ruling out of other 
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Figure 1 Breakdown of AED exposures returned from the DDD Study 
Group. Other 5 are diazepam, ethosuximide, clonazepam, clobazam 
and trihexyphenidyl. AED, antiepileptic drug; CBZ, carbamazepine; 
DDD, Deciphering Developmental Disorders; LTG, lamotrigine; LVT, 
levetiracetam; PHT, phenytoin, TOP, topiramate; VPA, valproate.
possible environmental and/or genetic causes of the presenting 
symptoms. In the past, the diagnosis has been accepted if there 
are normal cytogenetic studies. However, even chromosomal 
microarray (CMA) with a resolution of around 180 kb6 will 
not detect single gene disorders which occur with significant 
frequency in individuals presenting with structural and devel-
opmental abnormalities and could be enriched in families where 
epilepsy is a feature. Whole exome sequencing (WES) is a more 
detailed genetic test than CMA and involves sequencing the 
entire genetic code, base-by-base, for the majority of protein-
coding regions of the human genome (coverage depending on 
platform). The use of such genetic tests is likely to enhance the 
accuracy of the diagnosis of FACS by identifying additional or 
alternative diagnoses.
To date, there has been no systematic review of the comorbid 
presence of genetic variants in children exposed to AEDs. This 
information may therefore be useful to outline its role in facil-
itating diagnosis and optimal clinical management and it has 
implications, also, for studies which aim to determine terato-
genic status following in utero exposure to medications.
The Deciphering Developmental Disorders (DDD) Study used 
WES in over 13 000 children, of whom ~8000 also had exon 
resolution CMA, with a range of developmental disorders which 
were unexplained after clinical evaluation and baseline genetic 
tests including CMA in the majority of cases. Copy number vari-
ants (CNVs) were sought by analysis of the exome sequence in 
those not undergoing separate CMA analysis. After 1133 cases 
had been analysed, the study had identified a causative variant 
in 40% of cases.7 As a significant number of patients recruited 
to the study had been exposed to AEDs in utero, this data set 
presented an opportunity through which the comorbid presence 
of effects of AED exposure and presence of potential pathogenic 
variants could be investigated.
MeThOds
The study participants were a retrospective cohort of patients 
with developmental disorders exposed to AEDs in utero who 
have undergone WES as part of the DDD Study. A detailed 
overview of the DDD Study has been described previously,8 
but in brief, clinicians from UK genetic centres were invited to 
recruit patients with significant structural malformations and/or 
intellectual disability who remained undiagnosed after routine 
paediatric and genetic assessment to the study. Saliva samples 
were collected from the child and both parents and a stored 
DNA sample from the child and a trio of exomes sequenced. 
Patients were phenotyped by a Consultant Clinical Geneticist 
using Human Phenotype Ontology terms and comprehensive 
data were supplied for each patient, including details of medical 
history, maternal illness, and drug exposure during pregnancy 
and the main clinical features observed along with growth param-
eters and developmental milestones. Bioinformatic algorithms 
were used to identify variants within all genes known to cause 
developmental disorders at the time of the analysis. Re-analysis 
is undertaken periodically throughout the study as new bioin-
formatic algorithms and information about newly discovered 
genes became available. Variants considered to have contributed 
to the phenotype were fed back to the recruiting clinical genet-
icist and where appropriate were discussed with patients and 
validated in local NHS diagnostic laboratories. Clinicians from 
the regional centres were invited to study subsets of the data 
as Complementary Analysis Projects. The DDD Study group in 
Cambridge approved a Complementary Analysis Study Request 
for this study in February 2016.
A list of variants for the 42 patients exposed to AEDs in utero 
was provided by the DDD Study Group. These were compared 
with the patient’s available phenotypic data to assess whether they 
explained the patient’s phenotype. In addition, we performed 
further analysis of these variants by searching online databases, 
interrogating evolutionary conservation and performing in 
silico analyses. All variants were reported and analysed on the 
GRCh37/hg19 genome build. These methods were used to give 
a pathogenicity score to each variant according to the American 
College of Medical Genetics (ACMG) guidelines.9 Furthermore, 
referring clinicians were approached for patients identified to 
have pathogenic variants.
In addition to the DDD cohort, and as a source of additional 
genetic data, parents of a series of patients with FACS who had 
been referred to our Regional Genetics Centre were sent infor-
mation about this study and invited to participate by allowing 
access to their previously obtained CMA data. These results 
were reviewed for any pathogenic changes. The OGT ISCA v2 
8×60 k microarray was used in all cases.
resulTs
The DDD Study Group had completed WES on 46 eligible chil-
dren–parent trios by the data freeze of 4293 trios on 5 July 2016 
when the application for data was accepted. Figure 1 shows the 
breakdown of exposures. After exclusion of 4 trios due to no clear 
documentation of AED in utero exposure, 42 trios remained for 
analysis. This included 26 males and 16 females with a mean age 
at enrolment into DDD of 6 years and 8 months.
In parallel, 20 patients with a clinical diagnosis of FVS were 
identified from our Regional Genetics Centre and were invited 
to participate in the study. A positive response was received in 10 
cases (50%). These 10 cases included 4 males and 6 female cases, 
all of which had CMA analysis but not WES.
COpy nuMber vArIAnTs
There was one patient with a reported CNV (DECIPHER ID 
263311) from the DDD cohort, which was felt to be contributory 
to the child’s phenotype. This was a 7 Mb gain at the 1q21.1 locus 
(chr1:142540048–149765695)x3 encompassing the recurrent 
1q21.1 microdeletion region and including at least 128 genes. 
This CNV was maternally inherited although little phenotypic 
data were available for the mother. The mother in this case was 
taking 1200 mg VPA and 400 mg CBZ for post-traumatic seizures 
suggesting she was not affected by a genetic seizure disorder. The 
child’s features included undescended testes, hypospadias repair, 
overlapping toes, thin upper lip and downturned mouth. He did 
not have a typical facial phenotype for fetal valproate syndrome.
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The 1q21.1 recurrent microduplication syndrome (Online 
Inheritance in Man (OMIM) 612475) is well described in the 
literature and predisposes to learning disability, Autistic Spec-
trum Disorder (ASD), macrocephaly, hypospadias, hypertelorism 
and schizophrenia but is rarely associated with seizures.10 The 
patient had global developmental delay, ventriculomegaly, 
plagiocephaly, long palpebral fissures, hypospadias and thoracic 
scoliosis. The opinion from the referring clinician was that this 
child’s developmental delay was severe and a further explanation 
was sought from the 100,000 Genomes Project, although both 
the 1q21.1 microduplication and VPA exposure were thought to 
be contributory.
Analysis of the microarray data of 10 patients (online supple-
mentary table 1) with a FACS diagnosis known to our centre 
did not find any known pathogenic variants. All patients were 
exposed to VPA with seven exposures in monotherapy and three 
polytherapy (VPA+levetiracetam (LVT), VPA+vigabatrin and 
VPA+lamotrigine). There was one patient exposed to both 
VPA and LVT who had a 327 kb gain at 15q21.1 which does 
not contain any genes and is of uncertain significance (chr15: 
46,334,812–46,661,995)x3. This patient had moderate to severe 
learning difficulties, ventricular septal defect, hypermobility, left 
hip dysplasia, mild low frequency hearing loss and repetitive 
autistic traits, which could all be attributed to VPA exposure and 
the phenotype was therefore considered to be consistent with 
the original fetal valproate syndrome diagnosis.
single nucleotide variants (snvs)
There were 19/42 (45%) patients with reported SNVs from the 
DDD Study WES data. Six of these variants occurring in the 42 
patients (14%) were classified as pathogenic or likely pathogenic 
as per ACMG guidelines and thought to explain the participant’s 
phenotype either in full or partially, alongside the AED exposure 
(table 1). Across the AED exposure types, variants were found in 
2/15 (13%) VPA exposure cases and 3/14 (21%) CBZ exposed 
cases. Two further variants were initially thought to be patho-
genic on bioinformatic grounds however did not appear to be 
contributory to the patients’ phenotypes.
ClInICAl evAluATIOn OF IdenTIFIed vArIAnTs
A summary of the patients in whom variants were identified, their 
clinical and genetic findings and the details of their AED medica-
tion are summarised in table 1. Further details of ACMG pathoge-
nicity scores can be found in online supplementary table 2.
patient 1 nF1
This child had clinical appearances consistent with a diagnosis 
of Soto’s syndrome, although NSD1 testing was negative and 
bone age was normal. His occipitofrontal circumference (OFC) 
was on the 97th centile and he had a long chin with a thin upper 
lip. He did not have any other features suggestive of FACS and 
consensus opinion was a Sotos-like phenotype. He, and his 
mother, had a few faint cafe-au-lait spots but would not fulfil 
criteria for neurofibromatosis. This variant was considered 
contributory to phenotype.
This variant was considered contributory, but the phenotype 
was less severe than expected. Neither of these siblings had 
typical FVS facial features.
patient 4 neXMIF
This patient had previously been investigated for Angelman 
syndrome due to severe developmental delay, hand flapping and 
repetitive mannerisms. The phenotype was felt to be consistent 
with other patients previously described to have NEXMIF vari-
ants. He had a tented upper lip and short upturned nose but no 
facial features of FACS. He had autistic features and an alterna-
tive diagnosis was considered early on. His behavioural pheno-
type was thought to be in keeping with others with NEXMIF 
variants; however, a contribution of VPA to his learning difficul-
ties cannot be excluded.
patient 5 dCX
It was very difficult to separate the effects of prenatal CBZ 
exposure from the effects of the DCX variant. The grand-
mother of the index case had the DCX variant but did not have 
epilepsy. Three of her daughters inherited the DCX variant, had 
epilepsy and a variable degree of developmental disorder, and 
were on CBZ during their pregnancies. One of her daughters 
did not inherit the DCX variant and had normal development 
and no epilepsy. Of the three children in the third generation, 
who had prenatal exposure to CBZ, all have speech delay, two 
have inherited the DCX variant and also have epilepsy, one did 
not and has no epilepsy (online supplementary figure). This 
DCX variant has previously been reported as likely pathogenic 
(rs587783577) causing white matter heterotopia. There was also 
a maternally inherited variant of unknown significance (VUS) 
in SRCAP (ENST00000262518.4:c.3212T>C (p.Leu1071Pro)) 
in the index patient. Pathogenic variants of this gene cause 
Floating-Harbor syndrome (FHS) (OMIM 136140). A blended 
phenotype is possible, but neither the patient, nor her mother, 
have short stature, a key feature of FHS.
patient 6 ehMT1
This patient was felt to have a phenotype entirely consistent with 
the EHMT1 variant identified. She did not have typical features 
of FACS and an alternative diagnosis was considered early on. 
In this case, CBZ was taken for the management of bipolar 
affective disorder. Interestingly, Kleefstra syndrome has recently 
been reported as a phenocopy in a patient presumed to have 
fetal valproate syndrome highlighting that FACS should remain 
a diagnosis of exclusion.11
variants not contributory to phenotype
Patient 7 KIF5C
A 41 bp deletion in KIF5C (ENST00000435030.1:c.2679_2719
del) identified by WES causes frameshift and hence was thought 
likely to be pathogenic however did not correlate with clinical 
findings. This patient was known to have a maternally inher-
ited 16p12.2 deletion, which was pathogenic. This microdele-
tion syndrome is known to cause developmental delay, cognitive 
impairment and seizures, although a variable phenotype.12 He 
also has a paternally inherited 20q13.33 duplication of uncer-
tain significance. Both of these CNVs were identified by CMA 
prior to referral to DDD Study as neither variant was thought 
completely explanatory to the phenotype. WES also found a 
VUS in KMT2D (ENST00000301067.7:c.5980G>A (p.As-
p1994Asn)), a gene associated with Kabuki syndrome. He did 
not have typical features of either of these conditions so the 
SNVs in KIF5C and KMT2D were felt unlikely to be clinically 
significant.
patient 8 FOXp1
This patient’s facial and behavioural phenotype was not typical for 
FACS. The FOXP1 variant (ENST00000491238.1:c.1372C>T 
(p.Gln458Ter)), although a nonsense variant, was felt not 
adequate to explain entire the phenotype and FACS was felt 
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to possibly have contributed. Variants in this gene cause intel-
lectual disability with language impairment (OMIM 613670); 
however, she did not completely demonstrate this phenotype. 
She had occasional bouts of aggressive behaviour and dysmor-
phic features not consistent with FACS nor any obvious alterna-
tive diagnosis.
dIsCussIOn
This study is the first to investigate potential underlying genetic 
diagnoses using CMA or WES to identify a potential explanatory, 
or contributory causes, for the clinical phenotypes in children 
exposed to AEDs in utero who have developmental disorders. 
Clinically relevant SNVs (and one CNV) were identified in 17% 
(7/42) of individuals.
This high yield might be expected, given that these individuals 
were recruited into the DDD Study because clinicians felt that 
their symptoms remained unexplained by the diagnosis of FACS 
alone. However, this study demonstrates well that children 
exposed to AEDs in utero can, in some cases, have underlying 
genetic causes for their symptoms and therefore the prenatal 
AED exposure may be of no or of limited relevance. These 
results also emphasise that FACS should be a diagnosis of exclu-
sion following clinical assessment and appropriate investigation, 
which should include WES where available.
The clinical diagnosis of children with developmental disor-
ders is often difficult and the added complication of AED expo-
sure in utero may make the task even more challenging. The 
diagnostic guidelines for FACS were published by Dean et al1 
and have yet to be updated in the light of ever more sensitive 
newer genetic investigations (such as CMA and WES). These 
criteria stress that FACS is a diagnosis of exclusion citing normal 
karyotype and 22q11 studies as a prerequisite to diagnosis. It 
is reasonable to suggest, based on our findings here that those 
children diagnosed with FACS some time ago based on the Dean 
criteria could potentially be found to have an alternate genetic 
diagnosis if further investigation was undertaken with CMA 
or WES. Consistent with our work published here, in 2012, 
Douzgou et al13 reported on 80 children referred for a possible 
diagnosis of fetal alcohol syndrome. Using a combination of 
fluorescence in situ hybridisation and CMA, 9% of these chil-
dren were found to have an alternative genetic diagnosis.
As well as the implications for clinical diagnosis of the FACS, 
these results also have implications for research aimed at delin-
eating the risks associated with in utero exposure to medica-
tions. This has comprised case reports and series but also cohort 
studies or population studies. While the inclusion of a control 
group from the same source and excluding children with a 
known genetic diagnosis may assist in ensuring the results of 
such studies are not biased by the inclusion of children with 
physical and neurodevelopmental difficulties which are in fact 
not linked to the teratogenic exposure, the data presented here 
suggest that genetic testing should also be considered in future 
studies if completely reliable risk estimates are to be generated.
The current study is limited by a small sample size and almost 
certain recruitment bias as patients will probably have been 
entered into DDD Study due to clinical suspicion that their 
phenotype was not complete in keeping with FACS. Many less 
complex or more mildly affected FACS patients would not have 
been entered into study as clinicians would be confident with 
the FACS diagnosis. This most likely explains why some patients 
with DDD had complex phenotypes which did not specifically 
fit with current knowledge of FACS. The additional cases from 
the Regional Genetics Centre had more extensive phenotypic 
data available and were not selected on the basis of an unclear 
diagnosis, but rather were sequential patients attending a genetic 
clinic, however, WES data were not available for them.
Reverse phenotyping has been established as a useful tool in 
variant calling from exome data and describes clinical evaluation 
of a patient once again after the variant has been found.14 We 
feel this technique may be useful in rare disorders such as FACS 
although we must consider that a ‘negative’ exome does not 
completely rule out a contributing genetic cause in our patients. 
Further study using genome sequencing or epigenetic techniques 
may play a role in elucidating the complex genetics behind a 
FACS diagnosis.
COnClusIOn
This study is the first of its kind to analyse the exomes of a series 
of individuals with developmental disorders who were exposed 
to AEDs in utero. Using WES in those children with severe 
phenotypes or who were exposed to relatively low doses of AED 
(below 800 mg daily of VPA for instance) would be useful in 
identifying alternative diagnoses. This will also be important in 
establishing if there are any FACS ‘genocopies’ suggesting that 
a child may have a purely genetic disorder which mimics FACS. 
This would have both significant implications for genetic coun-
selling in future pregnancies and potentially for the processes 
currently used to determine teratogenic status of medications.
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